Table 1 Baseline Characteristics
| Â | BIS | BISVITD | P value |
|---|---|---|---|
N | 290 | 159 | - |
Age (years) (SD*) | 75.1 (5.7) | 73.6 (5.6) | 0.011 |
Women | 263 | 149 | 0.267 |
Body mass index (kg/m2) (SD*) | 26.3 (4.9) | 25.3(3.7) | 0.024 |
Bisphosphonate | Â | Â | Â |
- Etidronate | 89.3% | 95.0% | 0.042 |
- Alendronate | 10.7% | 5.0% | Â |
Years of bisphosphonates (SD*) | 5.9 (2.4) | 1 (0.0) | 0.001 |
Calcium (mg/day) | Â | Â | Â |
- supplement | 658.2 | 757.1 | 0.002 |
- dietary | 635.3 | 609.9 | 0.586 |
- total | 1266.0 | 1319.0 | 0.369 |
Previous exposure to | Â | Â | Â |
- estrogen | 37.6% | 30.4% | 0.127 |
- fluoride | 9.0% | 8.8% | 0.955 |
- calcitonin | 1.7% | 3.0% | 0.330 |
Previous fracture | 68% | 69% | 0.786 |
Weekly alcohol intake (ounces) | 1.63 | 1.26 | 0.537 |
Smoking history | 32% | 35% | 0.616 |
Corticosteroids | Â | Â | Â |
- systemic | 19.7% | 17.0% | 0.488 |
- inhaled | 12.4% | 14.5% | 0.539 |
Ever treated with | Â | Â | Â |
- non-steroidal anti-inflammatory | 39.7% | 35.2% | 0.356 |
- thyroxin | 12.6% | 15.7% | 0.393 |
β-blocker | 6.6% | 8.2% | 0.523 |
- sedative-hypnotic | 7.2% | 6.3% | 0.704 |
- thiazide | 7.2% | 6.3% | 0.704 |
- calcium-channel blocker | 1.0% | 2.5% | 0.227 |
- lipid-lowering agent | 0.3% | 2.5% | 0.036 |
- anticonvulsants | 0.7% | 1.3% | 0.541 |
- tamoxifen | 0.7% | 1.3% | 0.295 |
- immunosuppressant | 0.0% | 1.9% | 0.019 |
- chemotherapy | 0.0% | 0.0% | - |
Laboratory values | Â | Â | Â |
- 25(OH)D (ng/mL) | 32.9 | 31.3 | 0.493 |
- ALP(IU/L) | 90.7 | 94.0 | 0.474 |
- Calcium (mmol/L) | 2.36 | 2.36 | 0.903 |
- Phosphorus (mmol/L) | 1.13 | 1.14 | 0.539 |
Baseline BMD (g/cm 2 ) | Â | Â | Â |
- lumbar spine | 0.9287 | 0.8991 | 0.045 |
- femoral neck | 0.7031 | 0.6850 | 0.081 |